Meeting
2022 ASCO Genitourinary Cancers Symposium
Real-world experience of axitinib as second-line treatment in metastatic renal cell carcinoma: Analysis of the Swedish population.
Authors
Angela Strambi
Medical Affairs, Pfizer AB, Stockholm, Sweden
Angela Strambi , Maria Jakobsson , Fredrik Nilsson , Johannes Arpegard , Johan Dalén
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 315)
DOI
10.1200/JCO.2022.40.6_suppl.315
Abstract #
315
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).
First Author: Matthew Scott Ernst
Poster
2017 Genitourinary Cancers Symposium
Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
First Author: Igor Stukalin
Poster
2016 Genitourinary Cancers Symposium
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
First Author: Jose Manuel Ruiz Morales
Poster
2016 Genitourinary Cancers Symposium
Outcomes of second targeted therapy in metastatic renal carcinoma: A retrospective chart review in the EU.
First Author: Daniel Yick Chin Heng